Immunogenicity of Eight Dormancy Regulon-encoded Proteins of Mycobacterium Tuberculosis in DNA-vaccinated and Tuberculosis-infected Mice

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2006 Dec 6

PMID 17145953

Citations 70

Authors

Virginie Roupie

Marta Romano

Lei Zhang

Hannelie Korf

May Young Lin

Kees L M C Franken

Tom H M Ottenhoff

Michel R Klein

Kris Huygen

Affiliations

Soon will be listed here.

Abstract

Hypoxia and low concentrations of nitric oxide have been reported to upregulate in vitro gene expression of 48 proteins of the dormancy (DosR) regulon of Mycobacterium tuberculosis. These proteins are thought to be essential for the survival of bacteria during persistence in vivo and are targeted by the immune system during latent infection in humans. Here we have analyzed the immunogenicity of eight DosR regulon-encoded antigens by plasmid DNA vaccination of BALB/c and C57BL/6 mice, i.e., Rv1733c, Rv1738, Rv2029c (pfkB), Rv2031c/hspX (acr), Rv2032 (acg), Rv2626c, Rv2627c, and Rv2628. Strong humoral and/or cellular Th1-type (interleukin-2 and gamma interferon) immune responses could be induced against all but one (Rv1738) of these antigens. The strongest Th1 responses were measured following vaccination with DNA encoding Rv2031c and Rv2626c. Using synthetic 20-mer overlapping peptides, 11 immunodominant, predicted major histocompatibility complex class II-restricted epitopes and one K(d)-restricted T-cell epitope could be identified. BALB/c and (B6D2)F(1) mice persistently infected with M. tuberculosis developed immune responses against Rv1733c, Rv2031c, and Rv2626c. These findings have implications for proof-of-concept studies in mice mimicking tuberculosis (TB) latency models and their extrapolation to humans for potential new vaccination strategies against TB.

Citing Articles

Evaluation of three novel antigens and costimulatory agents for improvement of M. Tuberculosis specific interferon gamma release assays.

Schwarzlose-Schwarck S, Reinwald M, Bauer T, Hentschel F, Kiderlen T, Zapf D BMC Infect Dis. 2025; 25(1):188.

PMID: 39920589 PMC: 11806546. DOI: 10.1186/s12879-025-10577-3.

Tuberculosis vaccines and therapeutic drug: challenges and future directions.

An Y, Ni R, Zhuang L, Yang L, Ye Z, Li L Mol Biomed. 2025; 6(1):4.

PMID: 39841361 PMC: 11754781. DOI: 10.1186/s43556-024-00243-6.

Intranasal Immunization with a Recombinant Adenovirus Encoding Multi-Stage Antigens of Preferentially Elicited CD8 T Cell Immunity and Conferred a Superior Protection in the Lungs of Mice than Bacillus Calmette-Guerin.

Wang L, Kang J, Jiang H Vaccines (Basel). 2024; 12(9).

PMID: 39340053 PMC: 11436211. DOI: 10.3390/vaccines12091022.

Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development.

Chugh S, Bahal R, Dhiman R, Singh R NPJ Vaccines. 2024; 9(1):57.

PMID: 38461350 PMC: 10924964. DOI: 10.1038/s41541-024-00834-y.

A novel multistage antigens ERA005f confer protection against by driving Th-1 and Th-17 type T cell immune responses.

Fan X, Zhao X, Wang R, Li M, Luan X, Wang R Front Immunol. 2023; 14:1276887.

PMID: 38022539 PMC: 10662081. DOI: 10.3389/fimmu.2023.1276887.

References

Franken K, Hiemstra H, van Meijgaarden K, Subronto Y, den Hartigh J, Ottenhoff T . Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expr Purif. 2000; 18(1):95-9. DOI: 10.1006/prep.1999.1162. View

Lee B, Hefta S, Brennan P . Characterization of the major membrane protein of virulent Mycobacterium tuberculosis. Infect Immun. 1992; 60(5):2066-74. PMC: 257116. DOI: 10.1128/iai.60.5.2066-2074.1992. View

Geluk A, van Meijgaarden K, Franken K, Drijfhout J, DSouza S, Necker A . Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans. J Immunol. 2000; 165(11):6463-71. DOI: 10.4049/jimmunol.165.11.6463. View

van Pinxteren L, Cassidy J, Smedegaard B, Agger E, Andersen P . Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol. 2001; 30(12):3689-98. DOI: 10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4. View

Boon C, Li R, Qi R, Dick T . Proteins of Mycobacterium bovis BCG induced in the Wayne dormancy model. J Bacteriol. 2001; 183(8):2672-6. PMC: 95186. DOI: 10.1128/JB.183.8.2672-2676.2001. View

Tanghe A, DSouza S, Rosseels V, Denis O, Ottenhoff T, Dalemans W . Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun. 2001; 69(5):3041-7. PMC: 98258. DOI: 10.1128/IAI.69.5.3041-3047.2001. View

Bandera A, Gori A, Catozzi L, Degli Esposti A, Marchetti G, Molteni C . Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J Clin Microbiol. 2001; 39(6):2213-8. PMC: 88113. DOI: 10.1128/JCM.39.6.2213-2218.2001. View

Flynn J, Chan J . Tuberculosis: latency and reactivation. Infect Immun. 2001; 69(7):4195-201. PMC: 98451. DOI: 10.1128/IAI.69.7.4195-4201.2001. View

Vordermeier H, Harris D, Lathigra R, Roman E, Moreno C, Ivanyi J . Recognition of peptide epitopes of the 16,000 MW antigen of Mycobacterium tuberculosis by murine T cells. Immunology. 1993; 80(1):6-12. PMC: 1422108. View

10.

Fine P . Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995; 346(8986):1339-45. DOI: 10.1016/s0140-6736(95)92348-9. View

11.

Huygen K, Content J, Denis O, Montgomery D, Yawman A, Deck R . Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med. 1996; 2(8):893-8. DOI: 10.1038/nm0896-893. View

12.

Denis O, Lozes E, Huygen K . Induction of cytotoxic T-cell responses against culture filtrate antigens in Mycobacterium bovis bacillus Calmette-Guérin-infected mice. Infect Immun. 1997; 65(2):676-84. PMC: 176113. DOI: 10.1128/iai.65.2.676-684.1997. View

13.

Cunningham A, Spreadbury C . Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. J Bacteriol. 1998; 180(4):801-8. PMC: 106957. DOI: 10.1128/JB.180.4.801-808.1998. View

14.

Denis O, Tanghe A, Palfliet K, Jurion F, van den Berg T, Vanonckelen A . Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun. 1998; 66(4):1527-33. PMC: 108084. DOI: 10.1128/IAI.66.4.1527-1533.1998. View

15.

Yuan Y, Crane D, Simpson R, Zhu Y, Hickey M, Sherman D . The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci U S A. 1998; 95(16):9578-83. PMC: 21381. DOI: 10.1073/pnas.95.16.9578. View

16.

Jungblut P, Schaible U, Mollenkopf H, Zimny-Arndt U, Raupach B, Mattow J . Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol Microbiol. 1999; 33(6):1103-17. DOI: 10.1046/j.1365-2958.1999.01549.x. View

17.

Hu Y, Movahedzadeh F, Stoker N, Coates A . Deletion of the Mycobacterium tuberculosis alpha-crystallin-like hspX gene causes increased bacterial growth in vivo. Infect Immun. 2006; 74(2):861-8. PMC: 1360292. DOI: 10.1128/IAI.74.2.861-868.2006. View

18.

Demissie A, Leyten E, Abebe M, Wassie L, Aseffa A, Abate G . Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol. 2006; 13(2):179-86. PMC: 1391929. DOI: 10.1128/CVI.13.2.179-186.2006. View

19.

Romano M, DSouza S, Adnet P, Laali R, Jurion F, Palfliet K . Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine. 2006; 24(16):3353-64. DOI: 10.1016/j.vaccine.2005.12.066. View

20.

Achonu C, Jamieson F, Behr M, Lillebaek T, Khan K, Gardam M . Evidence for local transmission and reactivation of tuberculosis in the Toronto Somali community. Scand J Infect Dis. 2006; 38(9):778-81. DOI: 10.1080/00365540600664084. View